Ventripoint Reports on Use of VMS Heart Analysis System to Reliably Measure Remodeling of the Right Ventricle
TORONTO, ONTARIO--(Marketwired - Aug. 21, 2017) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the
"Company") (TSX VENTURE:VPT) announces that the cardiology group at Royal Free Hospital in London, UK has published a study
entitled "Two-dimensional knowledge-based volumetric reconstruction of the right ventricle documents short-term improvement in
pulmonary hypertension" in Echocardiography, volume 34, pages 817-824.
This study confirms the ability of the VMS Heart Analysis System (referred to in the paper as "two-dimensional knowledge-based
volumetric reconstruction or 2DKBR) to follow patients with enlarged right ventricles (RV) and accurately measure small but
medically-significant changes in volume and function. This ability to monitor clinical outcomes shortly after the initiation of
therapy is important to determine if the therapy is working well or if a new therapeutic approach is required. The VMS detected
the remodeling of the RV to reduce its size in patients who improved and an increase in RV size in patients with worse clinical
outcomes including death.
"Ventricular remodeling in PAH can be differentiated into two patterns: adaptive remodeling with concentric hypertrophy and
preserved function, and maladaptive remodeling with eccentric hypertrophy and worsening function. Our study shows that within
several months a change from one pattern to the other can occur with medical therapy," stated the authors.
The group concluded; "2DKBR can be reliably used in a busy clinical setting to follow-up right-ventricular indices in
pulmonary hypertension…"
About Ventripoint Diagnostics Ltd.
Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is
the first cost-effective and accurate tool for measuring heart function. The Corporation has developed a suite of applications
for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal
hearts - a multi-billion dollar market potential.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking
information that involves risk and uncertainties. All statements, other than statements of historical facts, which address
Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise
of business judgment as well as assumptions made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements.
These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in
these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise
publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or
to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable
assumptions, no assurance can be given that these expectations will materialize.